Medline ® Abstract for Reference 61
of 'Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer'
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D
Br J Cancer. 2005;93(7):740.
In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3-2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS (HR 1.9; 95% CI: 1.1-3.4, P = 0.019).
Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.